March 8, 2024
TOPLINE: A multicomponent strategy of nurse-led communication, home blood pressure monitoring, evidence-based treatment algorithms, and electronic health record tools improved systolic blood pressure (SBP) and non–high-density […]
March 7, 2024
The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug’s manufacturer, announced today. This is the second tocilizumab biosimilar […]
March 7, 2024
The prevailing view of menopause as an endocrine deficiency has led to a “disease-based model” that leads to over-medicalisation of this inevitable life transition, according to […]
March 7, 2024
WEST PALM BEACH, Fla. — Patient-reported outcomes (PROs) define the issues that matter to the patient, but their potential in multiple sclerosis (MS) is likely to […]
March 7, 2024
TOPLINE: The odds of having cognitive impairment may be increased among children with atopic dermatitis (AD), primarily among those with neurodevelopmental disorders, such as attention-deficit/hyperactivity disorder […]
March 7, 2024
A Danish study showing that about half of patients with newly diagnosed inflammatory bowel disease (IBD) had findings consistent with spondyloarthritis (SpA) was highlighted as one […]
March 7, 2024
The risk of developing a new autoimmune inflammatory rheumatic disease (AIRD) is greater following a COVID-19 infection than after an influenza infection or in the general […]
March 7, 2024
(Reuters) – GSK said on Thursday a study showed its experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms […]
March 7, 2024
(Reuters) -Boehringer Ingelheim will cap out-of-pocket costs for the company’s inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482
Next page